Credit: Washington University
By mapping the genetic evolution of cancer cells in patients with myelodysplastic syndromes who later died of leukemia, Timothy Graubert, MD, and Matthew Walter, MD, have found clues to suggest that targeted cancer drugs should be aimed at mutations that develop early in the disease.